- UK funding of cancer drugs: right, wrong of just confused? Deep Dive May 2017
- Multi-indication pricing: No longer mission impossible? Deep Dive Jul 2016
Pharmaphorum
- Hung parliament: Who will pharma negotiate with on new PPRS? Pharmaphorum 12 Jun 2017
- Brexit life sciences 'beauty contest' underway Pharmaphorum 9 Jun 2017
- UK election: what pharma wants Pharmaphorum 30 May 2017
- Just how much does the UK spend on medicines? Pharmaphorum 25 May 2017
- Behind the buzz of real-world data and real-world evidence Pharmaphorum 5 Apr 2017
- Budget impact and cost-effectiveness: Alternatives to NICE and NHSE proposals Pharmaphorum 17 Jan 2017
- Budget impact and cost-effectiveness: Can the UK learn from ICER in the US? Pharmaphorum 12 Jan 2017
- The budget impact of new medicines Pharmaphorum 10 Jan 2017
- Three NICE thresholds for cost-effectiveness: Does that make sense? Pharmaphorum 25 Nov 2016
- The PPRS medicines pricing scheme: Is it working for both sides? Pharmaphorum 8 Nov 2016
- International benchmarking and NICE Pharmaphorum 13 Oct 2016
- Sitting uncomfortably? The UK's PPRS and statutory schemes Pharmaphorum 31 Aug 2016
- PPRS and devolution: Over £60m to Greater Manchester? Pharmaphorum 10 Aug 2016
- Should industry pay for NICE Technology Appraisals? Pharmaphorum 1 Mar 2016
- End-of-life treatments: What will NICE accept? Pharmaphorum 8 Feb 2016
- The 'new' economics of drug pricing Pharmaphorum 8 Jan 2016
- Access to new medicines in Scotland Pharmaphorum 23 Dec 2015 and pdf
- Patient Access Schemes: A look behind the scenes Pharmaphorum 8 Dec 2015
- Value of health economists questioned Pharmaphorum 7 Oct 2015
- NICE aces Triennial Review but should it be scrutinised more often? Pharmaphorum 7 Sept 2015
- Where does all the PPRS money go? Pharmaphorum 4 Aug 2015
- NHS England making NICE look much nicer? Pharmaphorum 15 July 2015
- Access to new medicines: shifting the blame Pharmaphorum 1 Jun 2015
- Early access initiatives - one year on Pharmaphorum 28 Apr 2015
- Election fever in the UK: what it means to pharma Pharmaphorum 16 Apr 2015
- Stay or go? The UK's PPRS and the statutory scheme for pricing branded medicines 9 Mar 2015
- Value for money of Health Technology Assessment Pharmaphorum 23 Feb 2015
- Real world evidence for pricing and reimbursement: the potential of Systemic Anti-Cancer Therapy (SACT) data Pharmaphorum 15 Jan 2015
- International league tables and medicines Pharmaphorum 15 Dec 2014
- Stakeholder engagement in Value Based Pricing and Value Based Assessment Pharmaphorum 12 Nov 2014
- Political dynamite - England's cancer Drugs Fund Pharmaphorum 29 Oct 2014
- NICE and the 2015 General Election Pharmaphorum 22 Oct 2014
- Real world cost effectiveness: lessons from the MS risk sharing scheme Pharmaphorum 19 Sept 2014
- Who influences NICE technology appraisals? Pharmaphorum 28 Jul 2014
- Achieving market access in the UK with a little help from Patient Access Schemes Pharmaphorum 17 Jul 2014
- Early access - an expanding menu of options Pharmaphorum 12 Jun 2014
- First test case of NICE approach to Highly Specialised Technologies, Soliris (eculizumab) Pharmaphorum 5 Feb 2014
- Rare disease reimbursement needs a reasonable process, not a blunt rule Pharmaphorum 3 Feb 2014 £
- Getting to know the new NHS in England Pharmaphorum 12 Dec 2013
- Orphan Medicines: Special Treatment Required? NHE Magazine Nov/Dec 2012 £
Pharmaceutical Executive
- Licensing approval in Europe: New options for a new era Pharmaceutical Executive Oct 2015 £
- The Gatekeeper Pharmaceutical Executive Oct 2014 £
- What does the UK's 'New' PPRS Mean for Value Based Pricing Pharmaceutical Executive 20 Nov 2013
- NICE Around the World Pharmaceutical Executive Jul/Aug 2013
- A New Era for NICE Pharmaceutical Executive May 2013
- The Queen's English Pharmaceutical Executive Aug 2012
EyeforPharma
- Early Access to Medicines Scheme: Lessons from Keytruda EyeforPharma 21 Dec 2015
- Scotland: Doing things differently EyeforPharma 29 May 2015
- Early access: Taking stock of the options EyeforPharma 4 Mar 2015
- First steps on the way to earlier access EyeforPharma 7 Oct 2014
- Market access: How to engage emerging stakeholders EyeforPharma 6 Nov 2011
- Merging market access and launch planning EyeforPharma 25 Sept 2011
- Market access: the impact of HTAs on strategy EyeforPharma 1 Sept 2011
- The impact of Value Based Pricing on market access and patient compliance EyeforPharma 2 Aug 2011
- Pharma and the 'new' NHS: Getting the most from partnerships EyeforPharma 12 Jul 2011
- The 'new' NHS: What does it mean for pharma? EyeforPharma 13 Jun 2011
- Market access and Patient Access Schemes EyeforPharma 10 Aug 2010
Healthcare Finance
- Engaging Clinicians in Costing Healthcare Finance Sept 2012 £
- Clinical and Financial Risks with Patient Access Schemes Hospital Pharmacy Europe Iss 60 Jan/Feb 2012
PharmaTimes
- Dosh for Docs PharmaTimes Magazine Dec 2014
- PPRS rebate trail ends in a black hole PharmaTimes 30 Oct 2014
- A Cold Climate for NICE PharmaTimes 1 Dec 2009
- Assessing NICE's Expanding Role PharmaTimes Apr 2009
Pharmafile
These articles aren't available online, but if you would like to read any, drop me a line and I'll pass a copy along to you.
- Head to Head: NICE and the SMC Pharmafile Aug 2006
- Opportunities for Pharma from Choice in Primary Care Pharmafile October 2005
- Economic Burden of Chronic Pain Across Europe PainEurope 2011;3:4-5 (now reprinted as one of the 10 best articles in 10 years of PainEurope) £
- Economic Crisis and Pain PainEurope 2011;2:8-9
These articles aren't available online, but if you would like to read any, drop me a line and I'll pass a copy along to you.
- A European Perspective on the 2014 PPRS, Pharma Pricing and Reimbursement 2014;19(2):36-37 £
- The Innovation Scorecard in the UK: Are There Lessons for Other Countries? Pharma Pricing and Reimbursement 2013;18(10):296-297 £
- NICE International Five Years On, Pharma Pricing and Reimbursement 2013;18(8):230-231 £
- Evaluating Orphan Drugs: The NICE Approach, Pharma Pricing and Reimbursement 2013;18(7):220-201 £
- The Cancer Drugs Fund, Looking to the Future, Pharma Pricing and Reimbursement 2012; 17(8):224-226 £
- Judicial Review of Wet AMD Drugs Stirs Controversy, Pharma Pricing and Reimbursement 2012;7(7):191 £
- NICE End of Life Guidance - Three Years On, Pharma Pricing and Reimbursement 2012;17(3):68-69 £
- EUnetHTA Joint Action: Past, Present and Future, Pharma Pricing and Reimbursement 2011;16(12):356-357 £
- Ongoing Debate Over Proposed Off-label Use of Avastin, Pharma Pricing and Reimbursement 2011;16(7):191 £
- Joint Early Scientific Advice - Increase Prospects for Market Access? Pharma Pricing and Reimbursement 2010;15(11):335-337 £
- UK Department of Health Examines Off-label Use of Avastin to Cut Costs, Pharma Pricing and Reimbursement 2010;15(7):190-191 £
- The Future of Value Based Pricing in the UK, Pharma Pricing and Reimbursement 2010;15(6):176-177 £
- Use and Mis-Use of the US Threshold for Cost-Effectiveness, Pharma Pricing and Reimbursement 2010;15(4):94 £
- Interim Results of the Multiple Sclerosis Risk Sharing Scheme, Pharma Pricing and Reimbursement 2010;15(3):63 £
- UK Consultation on Innovation Pass Pilot, Pharma Pricing and Reimbursement 2010;15(2):36-37 £
- Regulators and HTA Agencies Drawing Closer in Europe, Pharma Pricing and Reimbursement 2010;15(2):48-49 £
- New Commissioning Support Appraisals Service in England, Pharma Pricing and Reimbursement 2010;15(1):2-3 £
- EC Network on HTA, Pharma Pricing and Reimbursement 2010;15(1):20-21
- Implications of the EC Inquiry into Pharmaceuticals, Pharma Pricing and Reimbursement 2009;14(11):391 £
- Financial Crisis and Health Policy: A Focus on HTA at Gastein, Pharma Pricing and Reimbursement 2009;14(11):323-333 £
- Diabetes and CHD – Challenges for Health Care Payers in the UK, Pharma Pricing and Reimbursement, 2004;(9):268-270 £
- Kennedy and OLS Report on State of Innovation, Pharma Pricing and Reimbursement 2009;14(8):224-245 £
- Globalisation in Health Technology Assessment, Pharma Pricing and Reimbursement 2009;14(8):244-245 £
- Happy Tenth Anniversary NICE, Pharma Pricing and Reimbursement 2009;14(4):94 £
- MS Risk Sharing Update, Pharma Pricing and Reimbursement 2009;14(4):95 £
- NICE: Jury Still Out After 10 Years, Pharma Pricing and Reimbursement 2009;14(4):102-104 £
- NICE is Growing Up, So Too is the SMC, Pharma Pricing and Reimbursement 2009;14(4):105-106 £
- EUnetHTA Reports on Three-Year EC Project, Pharma Pricing and Reimbursement 2009;14(1):41-43 £
- Thresholds for Cost Effectiveness - Where to Draw the Line? Pharma Pricing and Reimbursement 2009;14(1):41-43 £
- Rationing: A Focus on Europe, Pharma Pricing and Reimbursement 2008;13(12):352-353 £
- More Drugs to be Made Available on the NHS But for Some Patients At Their Own Cost, Pharma Pricing and Reimbursement 208;13(12):354-357 £
- The Impact of Abolishing Co-payments in Wales, Pharma Pricing and Reimbursement 2008;13(10):294-295 £
- Risk Sharing Schemes - The Australian Experience, Pharma Pricing and Reimbursement 2008;13(10):304-306 £
- Time to Top Up, Pharma Pricing and Reimbursement 2008;13(9):254-255 £
- Measuring Access to Medicines - A New Index, Pharma Pricing and Reimbursement 2008;13(9):270-271 £
- EuroNICE or EuroNASTY? Pharma Pricing and Reimbursement 2008;13(7):204-205 £
- What Can the US Learn from UK Risk Sharing? Pharma Pricing and Reimbursement 2008;13(4):95
- Funding Cancer Products - What Are the Options? Pharma Pricing and Reimbursement 2008;13(4):95
- Defining Risk Sharing, Pharma Pricing and Reimbursement 2008;13(3):78-80
- Commons Select Committee Delivers Second NICE Report, Pharma Pricing and Reimbursement 2008;13(2):30-31
- Velcade: The Rise of Risk-Sharing in the UK, Pharma Pricing and Reimbursement 2007;12(9):272-273
- NICE Tackling Use of Ineffective Technologies - Is More Needed? Pharma Pricing and Reimbursement 2007;12(3):74-76
- Renegotiation of the UK Quality and Outcomes Framework - Focusing on New Clinical Areas, Pharma Pricing and Reimbursement 2006;11(7):202-203
- Multiple Sclerosis Risk-Sharing - Four Years On, Pharma Pricing and Reimbursement 2006;11(4):100-101
- The MS Risk-Sharing Scheme – Eighteen Months On, Pharma Pricing and Reimbursement 2004;9(1):8-9
For transparency, those activities with £ are articles for which I received payment either directly, or where the research covered in the article was paid for. Where there is no symbol, I received no payment for the article, either directly or indirectly.
